Top Update Stories
Update
Could new biosimilars end Humira's reign as the best-selling drug in history?
By Arthur AllenThousands of patients with autoimmune diseases rely on Humira, at a list price of $6,600 a month, and could benefit from low-cost biosimilars that could save the health care system $9 billion a year, but will PBMs follow suit?










